Literature DB >> 17173339

Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.

Anthony O'Hagan1, Matt Stevenson, Jason Madan.   

Abstract

Probabilistic sensitivity analysis (PSA) is required to account for uncertainty in cost-effectiveness calculations arising from health economic models. The simplest way to perform PSA in practice is by Monte Carlo methods, which involves running the model many times using randomly sampled values of the model inputs. However, this can be impractical when the economic model takes appreciable amounts of time to run. This situation arises, in particular, for patient-level simulation models (also known as micro-simulation or individual-level simulation models), where a single run of the model simulates the health care of many thousands of individual patients. The large number of patients required in each run to achieve accurate estimation of cost-effectiveness means that only a relatively small number of runs is possible. For this reason, it is often said that PSA is not practical for patient-level models. We develop a way to reduce the computational burden of Monte Carlo PSA for patient-level models, based on the algebra of analysis of variance. Methods are presented to estimate the mean and variance of the model output, with formulae for determining optimal sample sizes. The methods are simple to apply and will typically reduce the computational demand very substantially. John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17173339     DOI: 10.1002/hec.1199

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  22 in total

1.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.

Authors:  Salah Ghabri; Françoise F Hamers; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

Review 2.  The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy.

Authors:  David B Rein; John S Wittenborn; Xinzhi Zhang; Benjamin A Allaire; Michael S Song; Ronald Klein; Jinan B Saaddine
Journal:  Health Serv Res       Date:  2011-04-14       Impact factor: 3.402

3.  Model-based economic evaluation for medical decision making: learn from the past and prepare for the future.

Authors:  Feng Xie
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

4.  Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.

Authors:  Chin Fen Neoh; Esin Senol; Ates Kara; Ener Cagri Dinleyici; Stuart J Turner; David C M Kong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-30       Impact factor: 3.267

5.  Exploring uncertainty in cost-effectiveness analysis.

Authors:  Karl Claxton
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.

Authors:  C F Neoh; E Senol; A Kara; E C Dinleyici; S J Turner; D C M Kong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-28       Impact factor: 3.267

7.  Economic evaluations with agent-based modelling: an introduction.

Authors:  Jagpreet Chhatwal; Tianhua He
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

8.  Continuous time simulation and discretized models for cost-effectiveness analysis.

Authors:  Marta O Soares; Luísa Canto E Castro
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

9.  Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care.

Authors:  Phil McEwan; Klas Bergenheim; Yong Yuan; Anthony P Tetlow; Jason P Gordon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

10.  Estimating dementia-free life expectancy for Parkinson's patients using Bayesian inference and microsimulation.

Authors:  Ardo van den Hout; Fiona E Matthews
Journal:  Biostatistics       Date:  2009-07-31       Impact factor: 5.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.